Showing results (11-20 of 28) with videos related to

Sort By:
Pageof 3
Nuclear Medicine and Biology|March 1, 2016
Comparison of (18)F-FET and (18)F-FLT small animal PET for the assessment of anti-VEGF treatment response in an orthotopic model of glioblastomaMette Kjoelhede Nedergaard, Signe Regner Michaelsen, Lara Perryman, et al.
Acta Neuropathologica Communications|November 29, 2025
Combined neocortical protein and morphological profiling of reactive microglia across Alzheimer's and Creutzfeldt-Jakob diseaseVladyslav Vadymovych Tkach, Nicolai Schou Bager, Signe Regner Michaelsen, et al.
Cancer Cell International|April 28, 2016
Combined EGFR- and notch inhibition display additive inhibitory effect on glioblastoma cell viability and glioblastoma-induced endothelial cell sprouting in vitroMikkel Staberg, Signe Regner Michaelsen, Louise Stobbe Olsen, et al.
Frontiers in Oncology|March 15, 2021
A Prognostic Model for Glioblastoma Patients Treated With Standard Therapy Based on a Prospective Cohort of Consecutive Non-Selected Patients From a Single InstitutionArmita Armina Abedi, Kirsten Grunnet, Ib Jarle Christensen, et al.
Plos One|February 14, 2015
18F-FET microPET and microMRI for anti-VEGF and anti-PlGF response assessment in an orthotopic murine model of human glioblastomaMette Kjoelhede Nedergaard, Signe Regner Michaelsen, Thomas Urup, et al.
Molecular Imaging and Biology|November 18, 2024
Using GeoMx DSP Spatial Proteomics to Investigate Immune Infiltration of NOD Mouse Islet and Exocrine CompartmentsHasim Tekin, Claes Lindhardt, Julie Christine Antvorskov, et al.
Cancer Investigation|February 3, 2018
Biomarkers in Recurrent Grade III Glioma Patients Treated with Bevacizumab and IrinotecanAnders Toft, Thomas Urup, Ib Jarle Christensen, et al.
Journal of Neuro-Oncology|July 16, 2025
Repeated responders to bevacizumab combination treatment in recurrent glioblastoma: a retrospective case studyMaya Jeje Schuang Lü, Signe Regner Michaelsen, Alessio Locallo, et al.
Molecular Oncology|January 24, 2018
Targeting glioma stem-like cell survival and chemoresistance through inhibition of lysine-specific histone demethylase KDM2BMikkel Staberg, Rikke Darling Rasmussen, Signe Regner Michaelsen, et al.
Molecular Oncology|March 6, 2020
Angiotensinogen promoter methylation predicts bevacizumab treatment response of patients with recurrent glioblastomaThomas Urup, Linn Gillberg, Katja Kaastrup, et al.
Pageof 3